Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GeoVax Ebola Vaccine Proven Effective in Rodent Models
100 Percent Protection Demonstrated in Preclinical Studies; Excellent Immune Responses and Safety Profile Observed
Sep 8, 2015, 1:04:00 PM
ATLANTA, GA - (NewMediaWire) - September 08, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel platform technology, announced today that its investigational Ebola vaccine candidate, GOVX-E301, provided 100 percent protection in guinea pigs and Syrian golden hamsters, two rodent models for Ebolavirus infections. The GOVX-E301 vaccine uses a recombinant modified vaccinia Ankara (MVA) vector to express non-infectious virus-like particles (VLPs) using genetic sequences from the 2014 Ebolavirus outbreak in West Africa. The studies were conducted in collaboration with, and funded in part by, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
"We are very pleased with the outcome of this study," commented Harriet L. Robinson, Ph.D., GeoVax's Chief Scientific Officer. "Through our ongoing research, we have anticipated that GeoVax's VLPs would elicit a strong immune response, and we had already demonstrated the production of Ebola VLPs in human cells. The next steps will be vaccination and challenge studies in nonhuman primates while also preparing for cGMP manufacturing of the vaccine for human clinical trials."
"GeoVax is committed to developing an Ebola vaccine with a superior safety and efficacy profile as compared to those of other vaccine candidates under development," said Robert T. McNally, Ph.D., GeoVax's President and Chief Executive Officer. "There are currently no approved vaccines for filoviruses (including Ebola virus) anywhere on the globe. The 2014/15 West African Ebola epidemic has caused over 28,000 infections, resulting in over 11,300 deaths. Considering the unpredictable and regular outbreaks of Ebolavirus infections, the development of vaccines that broadly protect against multiple filoviruses is a global priority. We believe our Ebola vaccine candidates have the potential to provide support in this effort, and we look forward to updating our shareholders as we move ahead."
About GeoVax's Ebola Vaccines
GeoVax began its Ebola vaccine development program in late 2014, using its non-infectious virus-like particle (VLP) technology and modified vaccinia Ankara (MVA) vector system originally developed for its HIV vaccine program. The Company first developed a vaccine for the recent epidemic in West Africa: a Zaire ebolavirus vaccine. In early 2015 the company expanded the program to include two other major filoviruses: Sudan Ebolavirus and Marburg virus, with the goal of developing a series of individual vaccines (monovalent) that will address each of the lethal strains of Ebola virus (Zaire, Sudan and Bundibugyo) and Marburg virus. The Company also plans to develop a multivalent vaccine, which will incorporate multiple monovalent vaccines to protect against the three strains of Ebola and Marburg with a single product. For testing purposes, GeoVax's first focus is on the monovalent vaccine for the Zaire strain of Ebola, designated GOVX-E301.
GeoVax's vaccine platform induces production of VLPs from the cells of the person receiving the vaccine. The production of VLPs in the person being vaccinated (in vivo) mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection should it appear. Producing VLPs in vivo also circumvents the need to purify virus-like particles for inoculation.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its novel vaccine platform. Current development programs are focused on vaccines against Ebola and Marburg viruses, and Human Immunodeficiency Virus (HIV). GeoVax believes its technology and vaccine development expertise is well-suited for a wide variety of human infectious diseases for which there is an unmet medical need, and intends to pursue expansion of its product pipeline.
Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the NIH-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax's HIV vaccines, in various doses and combinations, have been tested in about 500 humans. For more information, go to www.geovax.com.
Profit & loss statement ...
http://www.otcmarkets.com/stock/MOPN/filings
I'm not suggesting anything ,
Because he is about ready to change the call letters
issued 1,313,395,590 on sept 12 2014 since sold 256,450,000
Yes ... if you read reason for late posting, because they needed time to get finance together, and then they post with no information.... joke!
NO... all of O'Bs big talk, and not one thing about sales .. o' and by the way, did you see all the shares that he has sold .. what a line of crap he has been handing out.. IMO
Not one word of any new sales.... BS
http://www.otcmarkets.com/stock/MOPN/filings
Yes I see that ... Jamie is just full of BS ..can't put it any other way
Was told by a 3rd party , yield sign is coming down today
This is what happened to the last person that tried this with mopn shares.
Cliffe Bodden
http://www.marketwired.com/press-release/silver-star-capital-holdings-as-part-its-green-business-acquisition-strategy-acquires-926685.htm
http://www.forbes.com/sites/billsinger/2013/02/25/74-months-in-prison-for-securities-fraudster-who-targeted-foreign-investors/
This is what happened to the last person that tried this with mopn shares.
Never good for a ticker change in penny land .. the last time I talked with James he spoke of .20 a share ,without a reverse split .. wondered how he was going to do that? We may soon know.
That does not sound good for share holders IMO
Now that we have a pumper. Things may get interesting .IMO
Still no Q report ...How can they not even get that right.
Lets hope so... just such a broken record .... we should know in a few days
Not sure... Like you. I'm tired of all the information promised, that never seems to materialize.
Maybe next Thursday.
GeoVax Receives Grant From NIH for HIV Vaccine Program
http://www.marketwatch.com/story/geovax-receives-grant-from-nih-for-hiv-vaccine-program-2015-07-01
AFRICAN LEADERSHIP MAGAZINE to Present Two Prestigious Awards to GeoVax and Dr. Robert McNally
http://www.streetinsider.com/Press+Releases/AFRICAN+LEADERSHIP+MAGAZINE+to+Present+Two+Prestigious+Awards+to+GeoVax+and+Dr.+Robert+McNally/10680799.html
MOP and Indian Country Environmental Associates Form Strategic Alliance
Product Sales & Distribution and Joint Proactive Emergency Response Targeted
http://www.mopenvironmentalsolutions.com/news/
Reporting complete by Monday ... IMO
GeoVax Enters Into Research Collaboration Agreement with the NIH for Ebola/Marburg Vaccines
Collaboration with the National Institute of Allergy and Infectious Diseases to Provide Facilities, Expertise, and Resources for Animal Protection Studies
ATLANTA, GA, April 16, 2015 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced that it has entered into a Research Collaboration Agreement (the “Agreement”) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for development of GeoVax’s vaccines against Ebola and Marburg viruses.
GeoVax is developing both single-strain and multi-strain vaccines against Ebola and Marburg, a hemorrhagic virus similar to Ebola. These are recombinant modified vaccinia Ankara (MVA) vectored vaccines, designed to produce non-infectious virus-like particles (VLPs) containing the Ebola or Marburg virus matrix protein (VP40) and displaying the Ebola or Marburg virus glycoprotein (GP). The matrix protein forms VLPs displaying the glycoprotein, which is the target for protective antibody.
GeoVax has collaborated extensively with NIAID in the development of MVA vaccines against HIV. GeoVax’s MVA-vectored HIV vaccines, which also express non-infectious VLPs, were constructed in NIAID-developed vectors. Prior collaborations between NIAID and GeoVax have been highly productive and beneficial to the field of HIV vaccine development. The purpose of the Agreement is to extend the NIAID-GeoVax collaboration into Ebola and Marburg vaccine development, in order to accelerate the development of vaccines against filoviruses, the family of hemorrhagic viruses containing Ebola and Marburg.
Under the Agreement, NIAID will contribute materials, reagents, and scientific advice for vaccine construction. Where appropriate, NIAID will collaborate on the analysis of the recombinant MVA expression and stability, data analysis, and interpretation of these studies. GeoVax will construct and characterize MVA-Ebola and MVA-Marburg recombinants in vitro and prepare MVA Ebola and Marburg vaccines for animal studies. NIAID will then carry out animal protection studies in guinea pigs, hamsters, and non-human primates if appropriate.
Harriet L. Robinson, Ph.D., GeoVax’s Chief Scientific Officer, commented, “We are very pleased to extend our collaboration with NIAID to our Ebola and Marburg vaccine program. The research project covered by this agreement clearly aligns with NIAID’s mission to address domestic and global health problems and diseases, including newly emerging infectious diseases such as Ebola and Marburg. We anticipate beginning the animal studies contemplated by the research plan in the very near future.”
About NIAID
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website (www.niaid.nih.gov).
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our novel vaccine platform. Our current development programs are focused on vaccines against Ebola and Marburg viruses, and Human Immunodeficiency Virus (HIV). We believe our technology and vaccine development expertise is well-suited for a wide variety of human infectious diseases for which there is an unmet medical need, and we intend to pursue expansion of our product pipeline as resources permit.
Our vaccine platform supports production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. Producing non-infectious virus-like particles in the person being vaccinated circumvents the need to purify virus-like particles for inoculation. The production of virus-like particles in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection should it appear.
Clinical trials for GeoVax’s preventive HIV vaccines have been conducted by the U.S. National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax’s vaccines, in various doses and combinations, have been tested in 500 humans. For more information, go to www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent HIV or Ebola infection in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
Contact:
Adam S. Holdsworth
PCG Advisory Group
646-862-4607
www.pcgadvisory.com
GeoVax Labs (GOVX) Releases Quarterly Earnings Results, Hits Expectations
http://www.dakotafinancialnews.com/geovax-labs-govx-releases-quarterly-earnings-results-hits-expectations/113599/
GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine
Strategy Intended to Accelerate Development of an HIV Vaccine for the Americas and Western Europe
ATLANTA, GA - April 14, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced its intention to pursue a dual pathway for advancing its preventive clade B HIV vaccine into pivotal human efficacy trials.
Robert T. McNally, Ph.D., GeoVax's President & CEO, explained, "On April 1, 2015, we announced that the HIV Vaccine Trials Network (HVTN) approved the concept protocol for a Phase 1 trial of our clade B HIV vaccine, coupled with late boosts of our MVA (modified Vaccinia Ankara) vaccine with or without a gp120 protein vaccine. As explained in that announcement, protein boosts were used in the one partially successful HIV vaccine trial (RV144). The forthcoming trial, HVTN 114, is expected to begin enrolling patients in late 2015 and will be fully funded by the National Institute of Allergy and Infectious Diseases (NIAID). While we believe the HVTN and NIAID approach may be the financially prudent step for advancing our vaccine prior to committing U.S. taxpayer funds to a much larger Phase 2b efficacy trial, we are investigating all options to accelerate our vaccine directly into pivotal Phase 2b clinical trials."
In her talk at the World Vaccine Congress on April 8, 2015, GeoVax's Chief Scientific Officer, Dr. Harriet L. Robinson, presented data showing the continuing increase in the U.S. taxpayer cost burden of HIV care and treatment efforts in the United States -- rising from $12 billion in 2009 to nearly $17 billion in 2014 and showing no slowing growth trend. These figures alone clearly demonstrate the critical need for a vaccine solution purely from a financial point of view. But the costs to society of an HIV infection also include patient time, lost productivity, and physical and emotional distress to patients and their families.
Dr. Robinson's talk featured the favorable immune response, durability, and safety characteristics of GeoVax's GOVX-B11 vaccine as demonstrated in successful Phase 1 and Phase 2a clinical trials involving 500 individuals. She also reviewed the Company's preclinical protection studies in non-human primates demonstrating the best protection currently being achieved by any HIV vaccines advancing in human clinical trials.
Dr. McNally added, "Based on all of these considerations, we believe it is not only in the best interests of our shareholders, but for the country at large, that we pursue a development strategy to accelerate and expedite our vaccine directly into pivotal Phase 2b efficacy trials, without the need for evaluating additional boosting regimens. Our intention is not to replace any of the efforts of the HVTN or NIAID regarding the ongoing 'protein boost' strategy and the commencement of the HVTN 114 trial or subsequent trials to further develop this concept. Rather, we plan a parallel strategy to secure funding for commencing a Phase 2b efficacy trial of our un-boosted GOVX-B11 vaccine. Each of these approaches has its own merits, but we strongly believe that our vaccine is ready for Phase 2b clinical trials."
Dr. McNally concluded, "We look forward to implementing our updated clinical strategy and advancing our vaccine directly into a pivotal Phase 2b clinical trial. We have sought the counsel and advice of many key stakeholders and HIV specialists, and management and our Board of Directors have determined our new strategy is the best way to proceed. We look forward to communicating the success of this strategy as we implement it."
About GeoVax's HIV Vaccine
GOVX-B11 is a DNA/MVA HIV vaccine, designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. Both the DNA and MVA vaccines express the three major proteins of the HIV virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax's vaccines are unique in expressing virus-like particles that display the natural form of the trimeric membrane-bound form of the HIV-1 envelope glycoprotein. Preclinical and clinical studies suggest that this feature generates antibody that binds sufficiently tightly to HIV, a virus that is not easily recognized by antibody, to prevent transmission. Studies have also demonstrated that the antibody response elicited by the GeoVax vaccine is highly durable (long-lasting), another important feature for an effective HIV vaccine.
interesting ...
Not to be rude ,, I would not ask other people to do, what I'm not willing to do myself...
I don't care about that at this point .. what matters is someone knows something ,In order to be buying larger blocks...
Lookie .. lookie finish... volume again today,, I guess all of Jamie's talk may have been correct
With the way they have been talking on email...probably time to start making some more phone calls
After a long time .. truly believe something is actually happening .
I'm just not sure why someone as credible as Ygal Doron would be promoting MOPN, if he didn't have a lot to gain
Testimonials
Read what others are saying about our line of superior absorbents!
March 21, 2015
“I am a distributor of JPO Absorbents as of Monday the 9th of March, 2015. I am totally amazed with the products. I did 6 Demonstrations with 6 different locations in Pennsylvania and sold them all. We left with 5 drums of JPO Ultra Blend 300, 3 cases of the Ultra Blend 300, and a Bag of the Mop 201. Everyone that saw the demonstration was just as amazed as I was. I have been selling most of my adult life and have not had the success in one day that I have had with JPO Products. We are extremely happy with the success of the product and the owner of the Company, Jamie O’Brian.
Thank you for your Support!”
T. E.
Enzo’s Cleaning Solutions, LLC
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
“During four separate occasions we have had the opportunity to observe the MOP absorbent product’s performance. Three were hard surface spills of various hydrocarbon products (i.e. 30w oil, transmission fluid, heavy naphtha, diesel oil, and blended heavy sop oils). On each occasion the absorbents picked up all of the products leaving no apparent residue. We mixed water at some sights and the hydrophobic properties allowed the absorbent to hold the products while allowing the water to run free and clean of oil.
The other test was with booms and pillows in shore line fresh water. The booms and pillows performed above the standards established by other booms (1.e. polypropylene). The booms had excellent penetration and adequately contained the product spill.
The material is light weight and more economical than the competitive brands we have used. We are extremely pleased with its performance and cost, and would recommend serious consideration of the product before using an alternative.
R.F
Safety Specialist, BP Oil Company
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
“I used the mop 201 to clean out a 52? wide by 18' long pit. The pit had water in it and there was oil all over the water. The mop 201 absorbed all the oil off the water. We then raked the mop 201 off the water and disposed of it in a garbage bag. The water was then able to be pumped out of the pit and disposed of oil free. Thanks for the mop 201. It is a great product.”
J.D.
North Woodbury Township, PA
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
“I have had the pleasure of witnessing the power of these products several times. They are very easy to use and let me tell you THEY WORK.
The MOP201 was simply amazing it is incredible that the product itself refuses to absorb the water, but in the pit that we cleaned out it took all of the oil and grease and fuel spilled in and just removed it without much effort.
My favorite JPO product so far that i have seen is the ultra blend, that stuff just keeps trying to absorb anything it touches. We had a spill in the shop that sat there for years stained into the concrete. This stuff literally pulled out the oil that had seeped into the concrete as well as the spill we created.
Simply amazing stuff. Keep it up JPO I look forward to using more of your products.”
J. G.
THERMALBLADE